A Phase II Trial of Prednisone, Oral Etoposide, and Novantrone (PEN) as Initial Treatment of Non-Hodgkin's Lymphoma in Elderly Patients

References

• Kennedy B. J. Aging and cancer. Journal of Clinical Oncology 1988; 6: 1903–11
   PubMed Web of Science ®Google Scholar
• Baranovsky A., Myers M. H. Cancer incidence and survival in patients 65 years of age and older. CA-A Cancer Journal for Clinicians 1986; 36(1)26–41
   PubMed Web of Science ®Google Scholar
• Carbone A., Tirelli U., Volpe R., Zagonel V., Manconi R., Menin A., Trovo M., Grigoletto E. Non-Hodgkin's lymphoma in the elderly: A retrospective clinicopathologic study of 50 patients. Cancer 1986; 57: 2185–9
   PubMed Web of Science ®Google Scholar
• Tirelli U., Zagonel V., Serraino D., Thomas J., Hoerni B., Tangury A., Ruhl U., Bey P., Tubiana N., Breed W. P. M., Roozendaal K. J., Gagenbeek A., Hupperets P. S., Summers R. Non-Hodgkin's lymphomas in 137 patients aged 70 years or older: A retrospective European organization for research and treatment of cancer lymphoma group study. Journal of Clinical Oncology 1988; 6(11)1708–13
   PubMed Web of Science ®Google Scholar
• Tirelli U., Carbone A., Zagonel V., Veronesi A., Canetta R. Non-Hodgkin's lymphomas in the elderly: Prospective studies with specifically devised chemotherapy regimens in 66 patients. European Journal of Cancer and Clinical Oncology 1987; 23(5)535–40
   PubMedGoogle Scholar
• Carbone A., Volpe R., Gloghini A., Trovo M., Zagonel V., Tirelli U., Monfardini S. Non-Hodgkin's lymphoma in the elderly. Journal of Clinical Oncology 1990; 66: 1991–4
   Google Scholar
• Hancock B. W., Ailken M., Ross C. M. D., Dunsmore I. R. Non-Hodgkin's lymphoma in Sheffield 1971–1980. Clinical Oncology 1983; 9: 109–19
   PubMed Web of Science ®Google Scholar
• Foucar K., Armitage J. O., Dick R. R. Malignant lymphoma, diffuse mixed small and large cell: A clinicopathologic study of 47 cases. Cancer 1983; 51: 2090–9
   PubMed Web of Science ®Google Scholar
• Vose J. M., Armitage J. O., Weisenburger D. D., Bierman P. J., Sorensen S., Hutchins M., Moravec D. F., Howe D., Dowling M D., Mailliard J., Johnson P. S., Pevnick W., Packard W. M., Okerbloom J., Thompson R. F., Langdon R. M., Jr., Soori G., Peterson C. The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. Journal of Clinical Oncology 1988; 6(12)1838–44
   PubMed Web of Science ®Google Scholar
• Goss P. E. Non-Hodgkin's lymphoma in elderly patients. Leukemia & Lymphoma 1993; 10(3)147–56
   PubMed Web of Science ®Google Scholar
• Williams L., Lowenthal D. T. Drug therapy in the elderly. Southern Medical Journal 1992; 85: 127–31
   PubMed Web of Science ®Google Scholar
• Robert J., Hoemi B. Age dependence of the early phase pharmacokinetics of doxorubicin. Cancer Research 1983; 43: 4469–87
   Google Scholar
• Von Hoff D. D., Layard M. W., Basa P. Risk factors for doxorubicin induced congestive heart failure. Annals of Internal Medicine 1979; 91: 710–17
   PubMed Web of Science ®Google Scholar
• Dixon D. O., Neilan B., Jones S. E., Lipschitz D. A., Miller T. P., Grozea P. N., Wilson H. E. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: The southwest oncology group experience. Journal of Clinical Oncology 1986; 4(3)295–305
   PubMed Web of Science ®Google Scholar
• Benjamin R. S., Dukart G. The role of mitoxantrone in malignant disease. Pharmamanual (PharmaLibr), H. T. Mouridsen, Morristown, NJ 1987; 25
   Google Scholar
• Sonneveld P., Michiels J. J. Full dose chemotherapy in elderly patients with non-Hodgkin's lymphoma: a feasibility study using a mitoxantrone containing regimen. British Journal of Cancer 1990; 62: 105–8
   PubMed Web of Science ®Google Scholar
• Vorobiof D. A., Terblanche A. P., Falkson C. I., Falkson G. Cyclophosphamide, mitoxantrone, vincristine and prednisone in the treatment of non-hodgkin's lymphoma. Chung Hua i Hsueh Tsa Chih—Chinese Medical Journal 1988; 45(5)378–9
   Google Scholar
• Dansey R., Bezwoda W. R. CNOP versus CHOP in the treatment of intermediate grade and high grade malignant lymphoma. Fourth European Conference on Clinical Oncology (Ecco). 1987, Abstract 1013
   Google Scholar
• Brusamolino E., Bertini M., Guidi S., Vitolo U., Iverardi D., Merante S., Colombo A., Resegotti L., Bernasconi C., Ferrini P. R. CHOP versus CNOP (N = mitoxantrone) in non-Hodgkin's lymphoma: an interval report comparing efficacy and toxicity. Haematologica 1988; 73(3)217–22
   PubMedGoogle Scholar
• Chuang M. W., Tzeng C. H., Chiou T. J., Chiu C. F., Hsich R. K., Liu J. H., Chen P. M. A comparative trial of C-no-vantrone OP (CNOP) vs C-adriamycin OP (CHOP) in the treatment of stage II–IV malignant lymphoma—the preliminary report. Chung Hua i Hsueh Tsa Chih—Chinese Medical Journal 1988; 41(1)51–6
   Google Scholar
• Pavlovsky S., Santarelli M. T., Erazo A., Diaz Maquco J. C., Somoza N., Lluesma Gonalons M., Garcia Vela E. L., Corrado C., Magnasco H. Results of a randomized study of previously-untreated intermediate and high grade lymphoma using CHOP versus CNOP. Annals of Oncology 1992; 3(3)205–9
   PubMed Web of Science ®Google Scholar
• Stadtmauer E. A., Cassileth P. A., Gale R. P. Etoposide in Leukemia, lymphoma and bone marrow transplantation. Leukemia Research 1989; 13(8)639–50
   PubMed Web of Science ®Google Scholar
• Miller J. C., Einhom L. H. Phase II study of daily oral etoposide in refractory germ cell tumors. Seminars in Oncology 1990; 17(1)36–9
   PubMed Web of Science ®Google Scholar
• Goss, P. E. and The Metro Toronto Lymphoma Group. PEN (Prednisone, Etoposide and Novantrone) for treatment of non-Hodgkin's lymphoma (NHL) in elderly patients. Seminars in Hematology 1994; 31(2)
   Web of Science ®Google Scholar
• Hayward J. L., Carbone P. P., Heuson J-C. Assessment of response to therapy in advanced breast cancer. Cancer 1977; 39: 1289–94
   PubMed Web of Science ®Google Scholar
• Heinz R., Pawlicki M., Losonczy H., Varbiro M., Benedek S., Konopka L., Kre I., Brugiatelli M. Initial chemotherapy with an age-adjusted CHOP-schedule in non-Hodgkin lymphomas with unfavourable prognosis: A study of the IGCI. Haematologica (Pavia) 1986; 71: 473–9
   PubMedGoogle Scholar
• Kitamura K., Takaku F. Pirarubicin, a novel derivative of doxorubicin. THP-COP therapy for non-Hodgkin's lymphoma in the elderly. American Journal of Clinical Oncology 1990; 1: 915–9
   Google Scholar
• Watkin S. W., Green J. A. Non-Hodgkin's lymphoma. A four-drug regimen suitable for elderly patients with advanced disease. Acta Oncologica 1990; 29(6)733–7
   PubMed Web of Science ®Google Scholar
• Tigaud J. D., Demolombe S., Bastion Y, Byron P. A., Coiffer B. Ifosfamide continuous infusion plus etoposide in the treatment of elderly patients with aggressive lymphoma: a phase II study. Hematological Oncology 1991; 9(4–5)225–33
   PubMed Web of Science ®Google Scholar
• Tirelli U., Zagonel V., Errante D., Serraino D., Talamini R., De Cicco M., Carbone A., Monfardini S. A prospective study of a new combination chemotherapy regimen in patients older than 70 years with unfavorable non-Hodgkin's lymphoma. Journal of Clinical Oncology 1992; 10(2)228–36
   PubMed Web of Science ®Google Scholar
• McMaster M. L., Johnson D. H., Greer J. P., Wolff S. N., Hildreth C. R., Greco F. A., Hainsworth J. D. A brief-duration combination chemotherapy for elderly patients with poor-prognosis non-Hodgkin's lymphoma. Cancer 1991; 15: 1487–92
   Web of Science ®Google Scholar
• Salvagno L., Contu A., Bianco A., Endrizzi L., Schintu G., Olmeo N., Aversa S., Schiarion-Sileni V., Soraru M., Fiorentino M. V. A combination of mitoxantrone, etoposide and prednisone in elderly patients with non-Hodgkin's lymphoma. Annals of Oncology 1992; 3: 833–733
   PubMed Web of Science ®Google Scholar
• Caracciolo F., Petrini M., Capochiani E., Papineschi F., Grassi B. Third general chemotherapy with P-VABEC for aggressive non-Hodgkin's lymphoma of the elderly. Leukemia and Lymphoma 1993; 11: 115–8
   PubMed Web of Science ®Google Scholar
• O'Reilly S. E., Klimo P., Connors J. M. Low-dose ACOP-B and VABE: Weekly chemotherapy for elderly patients with advanced-stage diffuse large cell lymphoma. Journal of Clinical Oncology 1991; 9(5)741–7
   PubMed Web of Science ®Google Scholar
• Sonneveld P., Michiels J. J. Full dose chemotherapy in elderly patients with non-Hodgkin's lymphoma: a feasibility study using a mitoxantrone containing regimen. British Journal of Cancer 1990; 62: 105–8
   PubMed Web of Science ®Google Scholar
• O'Reilly S. E., Connors J. M., Howdle S., Hoskins P., Klasa R., Klimo P., Stuart D. S. In search of an optimal regimen forelderly patients with advanced stage diffuse large cell lymphoma: results of a phase II study of P/DOCE chemotherapy. Journal of Clinical Oncology 1993; 11: 2250–7
   PubMed Web of Science ®Google Scholar
• Martelli M., Guglieimi C., Coluzzi S., Avvisati G., Amadori S., Giovannini M., Torromeo C., Mandelli F. P-VABEC: a prospective study of a new weekly chemotherapy regimen for elderly aggressive non-Hodgkin's lymphoma. Journal of Clinical Oncology 1993; 11: 2362–9
   PubMed Web of Science ®Google Scholar
• Hainsworth J. D. Chronic administration of etoposide in the treatment of non-Hodgkin's lymphoma. Leukemia & Lymphoma 1993; 10: 65–72, (Suppl)
   PubMedGoogle Scholar
• Haak H. L., Gerrits W. B., Wijermans P. W., Kerkhofs H. Mitoxantrone, teniposide, chlorambucil and prednisone (MVLP) for relapsed non-Hodgkin's lymphoma. The impact of advanced age and performance status. Netherlands Journal of Medicine 1993; 42: 122–7
   PubMed Web of Science ®Google Scholar